ALXO · Alx Oncology Holdings Inc

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter.

One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.

One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025.

The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025.

One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.

One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.

One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.

One-third of the shares subject to the option vest on each of September 17, 2025, January 31, 2026 and June 30, 2026.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.09, inclusive.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6823 to $0.9234, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025.

Shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

All of the shares subject to the option vest on April 11, 2026.

All of the shares subject to the option vest on April 11, 2026.

All of the shares subject to the option vest on April 11, 2026.

All of the shares subject to the option vest on April 11, 2026.

The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials. Shares subject to the PSU vest on March 14, 2026.

The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials. Shares subject to the PSU vest on March 14, 2026.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The shares were sold to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2024.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025.

Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025.

One-fourth of the shares subject to the option vest on January 21, 2026 and 1/48 of the shares vest monthly thereafter.

Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025.

Shares subject to the option vest in 12 equal monthly installments beginning on February 21, 2025.

Shares subject to the option vest in 12 equal monthly installments beginning on February 21, 2025.

Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025.